An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19)
Reads0
Chats0
TLDR
In this paper , the authors reviewed the pleiotropic roles of the IL-6 pathway in lung damage and ARDS in severe COVID-19, and the rationale for IL6 signaling blockade at different levels.About:
This article is published in International Immunopharmacology.The article was published on 2022-01-01 and is currently open access. It has received 23 citations till now. The article focuses on the topics: Medicine & Cytokine storm.read more
Citations
More filters
Journal ArticleDOI
OMICRON: Virology, immunopathogenesis, and laboratory diagnosis
TL;DR: An overview of the biological and immunopathological properties of Omicron and its subvariants, its clinical signs and symptoms, Omicon and pediatrics, vaccines against OmicRON, re‐infection with Omicrons, diagnostic approaches and specific challenges of O micron in the successful control and management of the rapid global spread of this variant are provided.
Journal ArticleDOI
Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications
Clara Di Vito,F. Calcaterra,Nicolò Coianiz,Sara Terzoli,Antonio Voza,Joanna Mikulak,Silvia Della Bella,Domenico Mavilio +7 more
TL;DR: mounting evidence indicates that NK cell tissue distribution and effector functions could be affected by SARS-CoV-2 infection and that a prompt NK cell response could determine a good clinical outcome in COVID-19 patients.
Journal ArticleDOI
Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics
Yash Munnalal Gupta,O. V. Savytskyi,Mathew A. Coban,Amoghavarsha Venugopal,Vasili Pleqi,Caleb A. Weber,Rohit A. Chitale,Ravi Durvasula,Christopher E. Hopkins,Prakasha Kempaiah,Thomas R. Caulfield +10 more
TL;DR: In this paper , the authors highlight target hotspots and their potential agents, with the ultimate goal of using rational design of new therapeutics to not only end this pandemic but also uncover a generalizable platform for use in future pandemics.
Journal ArticleDOI
Anti-nucleocapsid antibodies enhance the production of IL-6 induced by SARS-CoV-2 N protein
Emi E. Nakayama,Ritsuko Kubota-Koketsu,Tadahiro Sasaki,Keita Suzuki,Kazuko Uno,Jun Shimizu,Toru Okamoto,Hisatake Matsumoto,Hiroshi Matsubara,Shoji Hashimoto,Toshio Tanaka,Hiromasa Harada,Masafumi Tomita,Mitsunori Kaneko,Kazuyuki Yoshizaki,Tatsuo Shioda +15 more
TL;DR: In this paper , the authors examined the cytokine production in COVID-19 patients by adding the lysate of SARS-CoV-2-infected cells to cultured macrophages or induced pluripotent stem cell-derived myeloid cells.
Journal ArticleDOI
Endocrine and metabolic complications of COVID-19: lessons learned and future prospects.
TL;DR: The short-term and long-term organ-based endocrinological complications of CO VID-19, the pathophysiology, the influence of each complication on COVID-19 prognosis, and potential therapeutic interventions based on current published data are reviewed.
References
More filters
Journal ArticleDOI
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
Chaomin Wu,Xiaoyan Chen,Yanping Cai,Jia’an Xia,Xing Zhou,Sha Xu,Han-Ping Huang,Li Zhang,Xia Zhou,Chunling Du,Yuye Zhang,Juan Song,Sijiao Wang,Yencheng Chao,Zeyong Yang,Jie Xu,Xin Zhou,Dechang Chen,Weining Xiong,Lei Xu,Feng Zhou,Jinjun Jiang,Chunxue Bai,Zheng Junhua,Yuanlin Song +24 more
TL;DR: Although high fever was associated with the development of ARDS, it was also associated with better outcomes among patients with ARDS and treatment with methylprednisolone may be beneficial for patients who develop ARDS.
Journal ArticleDOI
Effective treatment of severe COVID-19 patients with tocilizumab.
Xiaoling Xu,Mingfeng Han,Tiantian Li,Wei Sun,Dongsheng Wang,Binqing Fu,Yonggang Zhou,Xiaohu Zheng,Yun Yang,Xiuyong Li,Xiaohua Zhang,Aijun Pan,Haiming Wei +12 more
TL;DR: Preliminary data show that tocilizumab, which improved the clinical outcome immediately in severe and critical COVID-19 patients, is an effective treatment to reduce mortality.
Journal ArticleDOI
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.
Haibo Zhang,Haibo Zhang,Haibo Zhang,Josef M. Penninger,Josef M. Penninger,Yimin Li,Nanshan Zhong,Arthur S. Slutsky,Arthur S. Slutsky,Arthur S. Slutsky +9 more
TL;DR: The rationale for angiotensin-converting enzyme 2 (ACE2) receptor as a specific target is reviewed, and a number of pharmaceuticals already being tested are tested but a better understanding of the underlying pathobiology is required.
Journal ArticleDOI
Cytokine release syndrome in severe COVID-19.
John B. Moore,Carl H. June +1 more
TL;DR: Lessons from arthritis and cell therapy in cancer patients point to therapy for severe disease as discussed by the authors, which can be found in the article "More from Arthritis and Cell Therapy in Cancer Patients".
Journal ArticleDOI
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.
TL;DR: Tocilizumab is a blocker of IL-6R, which can effectively block IL- 6 signal transduction pathway, and is likely to become an effective drug for patients with severe COVID-19.